All News

A new research study from the Robert Wood Johnson Medical School showed that niclosamide ethanolamine salt (NEN) can burn the excess fat in the liver cells of mice through a process known as mitochondrial uncoupling. Fat accumulation in the liver is a typical characteristic of diabetic patients.

Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.

A study published in the American Journal of Preventive Medicine found that lack of awareness resulted in women over 65 and those who had undergone hysterectomy routinely undergoing a Pap test.

ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.

The study, published in Cancer Epidemiology, Biomarkers & Prevention, evaluated the influence of NSAIDs and statins on PSA levels in men with a high prostate cancer risk.

The molecule is being evaluated in crizotinib-resistant ALK-positive NSCLC patients. The results from the phase 1/2 trial with AP26113 were presented at the 2014 European Cancer Congress.

The study by Kaiser Permanente found that prescription practices were not much influenced by the decrease in fee-for-service payments for outpatient chemotherapy, due the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The next phase of New Hampshire's plan to bring managed care to the state's Medicaid program will not go into effect on January 1, 2015, as planned, due in part to concerns about the ability to ensure smooth transitions for those with complex medical cases to receive uninterrupted care.

The Cigna-NCCN collaboration will benefit about 12.5 million members.

The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.

A study published in a supplement to the Journal of Women's Health looks to the widespread impact of newer screening technologies to improve outcomes.

The rising cost of prescription drugs, CMS initiative updates, and successes in home and community-based services for dual Medicare and Medicaid beneficiaries were discussed at the America's Health Insurance Plans' National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC.

Deaths from overdoses on heroin rose in 28 states with just over half the nation's population from 2010 to 2012, but deaths from overdoses on prescription opioid pain relievers fell slightly during that period.

Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.

The study, published online in JAMA Otolaryngology - Head & Neck Surgery, found a significant increase in the rate of head and neck cancers in individuals carrying a BRCA mutation.

A review published in Neuro-Oncology provides insight into some of the molecules being developed to target IL13Rα2 in brain tumors.

Hepatitis C and the price of Sovaldi were, understandably, the main focus of aconversation on rising prescription drug prices at the America's Health Insurance Plans' National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC.

As Texas health officials monitor 80 people for symptoms of the Ebola virus, the question arises: could this public health threat have avoided if the ER at Texas Presbyterian admitted the patient with the disease when it first had the chance? Was the patient's insurance status an issue, as some have suggested?

A new information governance framework of 8 principles from the American Health Information Management Association aims to help meet the patient care, safety, and operational goals of healthcare organizations.

ASCO has called for raising awareness to control obesity, as it is not just a risk factor for developing diabetes but also for cancer.

At $531 billion, Medicaid is the second largest piece of healthcare spending and cannot be pushed off to be thought about another day, Cindy Mann, JD, CMS deputy administrator and director of the Center for Medicaid and CHIP Services, said at the America's Health Insurance Plans' National Conferences on Medicare and Medicaid and Dual Eligibles Summit.

No state-run exchange, no subsidy for health coverage. That's what a federal judge in Oklahoma ruled yesterday, marking the second such ruling against a key component of the Affordable Care Act and setting up a potential return trip to the US Supreme Court to decide the fate of a key piece of the law.

The first round of Open Payments data, known as the Physician Payments Sunshine Act, were made public Tuesday and revealed 4.4 million payments valued at nearly $3.5 billion paid out to 546,000 individuals and almost 1346 teaching hospitals.

A ballot question to limit narrow networks in South Dakota evokes the outcry that occurred when managed care first sought to rein in costs in the 1990s. Critics of the measure say its passage will push up premiums 20 percent.

Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.

At the America's Health Insurance Plans' National Conference on Medicare and Medicaid and Dual Eligibles Summit in Washington, DC, Patrick Conway, deputy administrator for innovation and quality and chief medical officer for CMS, spoke on the future of delivery system reform.

Phase 3 trial data from the ROMANA trials, presented at ESMO found that anamorelin improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia.

Plans designed specifically for disabled dual-eligible Medicare and Medicaid beneficiaries are not necessarily enough to reduce use of costly services, according to a new report from the Government Accountability Office.

Xalkori, currently approved for treating NSCLC with ALK rearrangements, reduced the tumor size in nearly 75% of the patients and also extended the remission period.

The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.